Checkpoint blockade in esophagogastric cancer
Copyright policy )Checkpoint blockade in esophagogastric cancer
There are few effective treatment options for metastatic esophagogastric adenocarcinomas after progression on second‐line chemotherapy. Immune checkpoint blockade therapy is a promising treatment strategy for selected advanced esophagogastric cancer, and the PD‐1 inhibitor pembrolizumab has recently been approved for metastatic or recurrent gastric or gastroesophageal junction cancer that has progressed beyond second‐line systemic therapy. We review the current data supporting immune checkpoint blockade therapy in advanced esophagogastric adenocarcinoma.
- Memorial Sloan Kettering Cancer Center United States
- New York Medical College United States
Stomach Neoplasms, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humans, CTLA-4 Antigen, Esophagogastric Junction, Immunotherapy, Adenocarcinoma, B7-H1 Antigen, Randomized Controlled Trials as Topic
Stomach Neoplasms, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humans, CTLA-4 Antigen, Esophagogastric Junction, Immunotherapy, Adenocarcinoma, B7-H1 Antigen, Randomized Controlled Trials as Topic
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).10 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!